Risk Factors Update Summary

• Research and development expenses decreased from $97.2 million in 2022 to $93.1 million in 2023.
• The addition of cybersecurity risks highlights potential threats to data security, operations, and financial condition.
• Cash and cash equivalents decreased from $84.3 million in 2022 to $47.3 million in 2023.
• A worldwide license agreement grants non-exclusive licenses for certain patent rights and know-how. This may enhance the development of iPSC-derived therapies for inflammatory and autoimmune diseases.
• Failure to prevent or mitigate security breaches could lead to significant liability under state and federal laws.
• Accumulated deficit increased from $519 million to $655 million.
• The addition of the Autoimmune License, Reprogramming License, and Differentiation License from FCDI enhances our cell differentiation capabilities.
• The company's reliance on third-party providers for information technology systems poses risks of cyberattacks.
• Number of employees decreased from 184 to 165 as of March 2024.
• The company's patent applications have increased from 126 to 145, indicating a focus on intellectual property protection.
• The company initiated its first clinical trial for CNTY-101 in patients with moderate to severe SLE.
• The number of shares of common stock has increased from 144 to 235, potentially impacting ownership concentration.
• The company reported results for 7 R/R lymphoma patients dosed with 100 million and 300 million cells of CNTY-101.
• The company entered into an exclusive license with FCDI for cancer immunotherapeutics.